Fibroban 5mg Injection

Fibroban 5mg injection contains the active ingredient tirofiban HCl. It is an antiplatelet medication primarily used to prevent or treat conditions related to abnormal blood clotting, particularly in situations with high risk of thrombosis. It is often administered alongside percutaneous coronary intervention (PCI), commonly known as angioplasty, to help prevent blood clot formation during the procedure. The medication may sometimes be used to manage thrombocytopenia, a condition characterised by low platelet counts.

Fibroban 5mg injection is contraindicated in patients with known hypersensitivity or allergy to tirofiban HCl or any components of the formulation. As a potent antiplatelet agent, it is contraindicated in patients with active bleeding disorders or active bleeding episodes. It is generally contraindicated in patients with a history of haemorrhagic stroke, as it may increase the risk of recurrent intracranial bleeding. Patients who have undergone major surgical procedures or experienced significant trauma within the preceding six weeks may be at higher risk of bleeding complications and are generally considered contraindicated for this medication.

Fibroban 5mg injection should be used with caution in patients with renal impairment, and dosage adjustment may be necessary. Individuals with known bleeding disorders or conditions predisposing to bleeding, such as haemophilia or von Willebrand disease, should generally not receive this medication. It may increase the risk of intracranial bleeding, therefore it is typically contraindicated in patients with known intracranial neoplasms or aneurysms.

The medication can be used in elderly patients but with caution, as age-related physiological changes may increase bleeding risk. Fibroban 5mg injection is typically not used in paediatric populations, as its safety and efficacy in children have not been well established.

Fibroban 5mg injection is used in the following: Acute coronary syndromes (ACS) Percutaneous coronary intervention (PCI) Thrombocytopenia management Ischemic stroke Coronary artery bypass grafting (CABG) Adjunctive treatment (high-risk patients)

Fibroban 5mg injection works by inhibiting the glycoprotein IIb/IIIa receptor on the surface of platelets. This receptor plays a crucial role in platelet aggregation and clot formation. By blocking this receptor, tirofiban helps prevent the formation of blood clots.

Tirofiban is typically administered intravenously (IV), giving it directly into a vein. It is usually administered in a healthcare setting, such as a hospital, where medical professionals can closely monitor the patient.

Fibroban 5mg injection causes some side effects like all medications, although not everyone will experience them. Serious Bleeding Thrombocytopenia Allergic reactions Low blood pressure Back pain or chest Pain Common Bleeding at the injection site Nausea Headache Fever Pain or swelling at injection site Chest discomfort or tightness

Fibroban 5mg injection should be used with caution due to its potential to increase bleeding risk. Patients with bleeding disorders, recent surgery, or a tendency to bleed easily should be vigilant. Monitoring for allergic reactions, low blood pressure, and platelet counts is essential, and kidney and liver function should be checked. Medication interactions, especially with blood thinners, require careful management. Pregnant or breastfeeding individuals should consult their healthcare provider before using tirofiban. Platelet function and cardiac monitoring may be necessary during treatment. Knowing the location of the nearest emergency medical facility is important, and proper IV administration is crucial.